Roge­rio Vi­val­di jumps from Biover­a­tiv buy­out to lead­ing Flag­ship-seed­ed Sig­ilon's Holy Grail pur­suit

Back in April, Sig­ilon CEO Paul Wot­ton told me that the $473 mil­lion deal he had struck with Eli Lil­ly helped high­light the up­start’s ap­proach to de­vel­op­ing a new kind of stem cell ther­a­py for di­a­betes.

“I think we’ve kind of dis­cov­ered the Holy Grail to make cell ther­a­py a re­al­i­ty,” Wot­ton said about their Flag­ship-seed­ed plat­form, which came out of the lab of MIT’s pro­lif­ic Bob Langer. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER